Abivax股价下跌,此前竞争对手吉利德科学的口服药物在中期肠道疾病试验中取得成功,该股最新跌幅为6.8%——交易员
Abivax股价下跌,此前竞争对手吉利德科学的口服药物在中期肠道疾病试验中取得成功,该股最新跌幅为6.8%——交易员
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.